On Monday, Tandem Diabetes Care stock received an upgrade to its Relative Strength (RS) Rating, from 68 to 78.
This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 in the early stages of their moves. See if Tandem Diabetes Care stock can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Is Tandem Diabetes Care Stock A Buy?
Tandem Diabetes Care stock broke out earlier, but is now trading about 4% below the prior 31.07 entry from a cup with handle. If a stock you're tracking clears a buy point then declines 7% or more below the original entry price, it's considered a failed base. It's best to wait for the stock to form a new pattern and breakout. Also understand that the latest consolidation is a later-stage base, which makes it riskier to establish a new position or add shares to an existing one.
The insulin delivery and diabetes technology company showed 0% EPS growth in its most recent report. Revenue rose -11%.
Tandem Diabetes Care stock earns the No. 65 rank among its peers in the Medical-Products industry group. DexCom, Boston Scientific and Integer Holdings are among the top 5 highly rated stocks within the group.
